Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy

American Journal of Hypertension

Volumn 25, Issue 12, 2012, Pages 1242-1248

  Tian, Jing ^a   Wang, Jingfeng ^a   Li, Yan ^a   Villarreal, Daniel ^b   Carhart, Robert ^b   Dong, Yanbin ^c   Wen, Yanling ^a,d   Liu, Kan ^b  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

blood pressure; brachial artery flow mediated dilation; early intensive insulin therapy; hypertension; type 2 diabetes; vascular endothelial dysfunction; von Willebrand factor

Indexed keywords

INSULIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BRACHIAL ARTERY; CLINICAL PROTOCOL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION;

ADULT; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CHINA; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VON WILLEBRAND FACTOR;

EID: 84869205085     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.122     Document Type: Article

References (35)

1. Vinik AI, Vinik E. Prevention of the complications of diabetes. Am J Manag Care. 2003, 9(3 Suppl): S63-S80; quiz S81-S4. (Pubitemid 36401621)
2. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S; HOPE investigators. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48:1749-1755. (Pubitemid 41317828)
3. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 2010; 105:373-377.
4. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288:2579-2588. (Pubitemid 35386893)
5. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. (Pubitemid 351831357)
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-139.
7. Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99:4i-20i.
8. Tian J, Wen Y, Yan L, Cheng H, Yang H, Wang J, Kozman H, Villarreal D, Liu K. Vascular endothelial dysfunction in patients with newly diagnosed type 2 diabetes and effects of 2-year and 5-year multifactorial intervention. Echocardiography 2011; 28:1133-1140.
9. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27:1028-1032. (Pubitemid 38579760)
10. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31:1927-1932.
11. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 2008; 371:1725-1726. (Pubitemid 351697932)
12. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371:1753-1760. (Pubitemid 351697950)
13. American Diabetes Association. Position statement: standards of medical care patients with diabetes mellitus. Diabetes 2002; 25:S33-S49.
14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393. (Pubitemid 36159355)
15. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57:2496-2504.
16. Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes. N Engl J Med 2000; 342: 381-389.
17. Writing Team For The Diabetes Control And Complications Trial/Epidemiology Of Diabetes Interventions And Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
18. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473:317-325.
19. Liu K, Paterson AJ, Chin E, Kudlow JE. Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death. Proc Natl Acad Sci USA 2000; 97:2820-2825. (Pubitemid 30159255)
20. Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, Mito S, Arozal W, Sukumaran V, Laksmanan AP, Soetikno V, Kodama M, Aizawa Y. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev 2010; 6:280-290.
21. Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, Boulanger CM. Microparticles, vascular function, and atherothrombosis. Circ Res 2011; 109: 593-606.
22. Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol 2009; 53:2315-2323.
23. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117:1449-1459. (Pubitemid 351501497)
24. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43:599-606.
25. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 2011; 9:899-908.
26. van Loon JE, Kavousi M, Leebeek FW, Felix JF, Hofman A, Witteman JC, de Maat MP. von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. J Thromb Haemost 2012; 10:1262-1269.
27. Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Döring A, Löwel H, Koenig W; MONICA/KORA Study Group. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006; 26:398-405. (Pubitemid 43732206)
28. Yoshida M, Tomiyama H, Yamada J, Matsumoto C, Odaira M, Shiina K, Yamashina A. Relationship of insulin resistance to macro-and microvasculature reactivity in hypertension. Am J Hypertens 2010; 23:495-500.
29. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001; 276:30392-30398.
30. Maeno Y, Li Q, Park K, Rask-Madsen C, Gao B, Matsumoto M, Liu Y, Wu IH, White MF, Feener EP, King GL. Inhibition of insulin signaling in endothelial cells by protein kinase C-induced phosphorylation of p85 subunit of phosphatidylinositol 3-kinase (PI3K). J Biol Chem 2012; 287:4518-4530.
31. Rajwani A, Ezzat V, Smith J, Yuldasheva NY, Duncan ER, Gage M, Cubbon RM, Kahn MB, Imrie H, Abbas A, Viswambharan H, Aziz A, Sukumar P, Vidal-Puig A, Sethi JK, Xuan S, Shah AM, Grant PJ, Porter KE, Kearney MT, Wheatcroft SB. Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes 2012; 61:915-924.
32. Franklin VL, Khan F, Kennedy G, Belch JJ, Greene SA. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia 2008; 51:353-360.
33. Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 2005; 25:963-976. (Pubitemid 40917929)
34. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
35. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005; 127:2254-2263.